Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ferenc G Rick, Norman L Block & Andrew V Schally. (2013) Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opinion on Pharmacotherapy 14:16, pages 2237-2247.
Read now
Read now
Aijaz Parray, Hifzur R Siddique, Sanjeev Nanda, Badrinath R Konety & Mohammad Saleem. (2012) Castration-resistant prostate cancer: potential targets and therapies. Biologics: Targets and Therapy 6, pages 267-276.
Read now
Read now
David Shapiro & Basir Tareen. (2012) Current and emerging treatments in the management of castration-resistant prostate cancer. Expert Review of Anticancer Therapy 12:7, pages 951-964.
Read now
Read now
Articles from other publishers (20)
Yuwan Zhao, Zhuo Li, Huancheng Tang, Shanhong Lin, Wenfeng Zeng, Dongcai Ye, Xin Zeng, Qiuming Luo, Jianwei Li, Zhixian Ao, Jierong Mo, Lixin Chen, Yiqiu Yang, Yunsheng Huang & Jianjun Liu. (2021) [Mn(PaPy2Q)(NO)]ClO4, a Near-Infrared Light activated release of Nitric Oxide drug as a nitric oxide donor for therapy of human prostate cancer cells in vitro and in vivo. Biomedicine & Pharmacotherapy 137, pages 111388.
Crossref
Crossref
Chi-Ming Liu, Chiu-Li Kao, Yu-Ting Tseng, Yi-Ching Lo & Chung-Yi Chen. (2017) Ginger Phytochemicals Inhibit Cell Growth and Modulate Drug Resistance Factors in Docetaxel Resistant Prostate Cancer Cell. Molecules 22:9, pages 1477.
Crossref
Crossref
Charles Dai, Hannelore Heemers & Nima Sharifi. (2017) Androgen Signaling in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine 7:9, pages a030452.
Crossref
Crossref
Sakthivel Muniyan, Siu-Ju Chen, Fen-Fen Lin, Zhengzhong Wang, Parmender P. Mehta, Surinder K. Batra & Ming-Fong Lin. (2015) ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. Cellular Signalling 27:11, pages 2261-2271.
Crossref
Crossref
Laura Caboni, Billy Egan, Brendan Kelly, Fernando Blanco, Darren Fayne, Mary J. Meegan & David G. Lloyd. (2013) Structure–Activity Relationships in Non-Ligand Binding Pocket (Non-LBP) Diarylhydrazide Antiandrogens. Journal of Chemical Information and Modeling 53:8, pages 2116-2130.
Crossref
Crossref
Roberta Ferraldeschi, Nima Sharifi, Richard J. Auchus & Gerhardt Attard. (2013) Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer. Clinical Cancer Research 19:13, pages 3353-3359.
Crossref
Crossref
G. L. Gravina, F. Marampon, P. Muzi, A. Mancini, M. Piccolella, P. Negri-Cesi, M. Motta, A. Lenzi, E. Di Cesare, V. Tombolini, E. A. Jannini & C. Festuccia. (2013) PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocrine Related Cancer 20:3, pages 321-337.
Crossref
Crossref
Nima Sharifi. (2013) Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer. Molecular Endocrinology 27:5, pages 708-714.
Crossref
Crossref
Hao Li, Matthew R. Redinbo, Madhukumar Venkatesh, Sean Ekins, Anik Chaudhry, Nicolin Bloch, Abdissa Negassa, Paromita Mukherjee, Ganjam Kalpana & Sridhar Mani. (2013) Novel Yeast-based Strategy Unveils Antagonist Binding Regions on the Nuclear Xenobiotic Receptor PXR. Journal of Biological Chemistry 288:19, pages 13655-13668.
Crossref
Crossref
James Robert Krycer & Andrew John Brown. (2013) Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1835:2, pages 219-229.
Crossref
Crossref
Rosalba Minelli, Roberta Cavalli, Leigh Ellis, Piergiorgio Pettazzoni, Francesco Trotta, Eric Ciamporcero, Giuseppina Barrera, Roberto Fantozzi, Chiara Dianzani & Roberto Pili. (2012) Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European Journal of Pharmaceutical Sciences 47:4, pages 686-694.
Crossref
Crossref
Rui Li, Kristen Evaul, Kamalesh K. Sharma, Kai-Hsiung Chang, Jennifer Yoshimoto, Jiayan Liu, Richard J. Auchus & Nima Sharifi. (2012) Abiraterone Inhibits 3β-Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer. Clinical Cancer Research 18:13, pages 3571-3579.
Crossref
Crossref
Nima Sharifi. (2023) The 5α-Androstanedione Pathway to Dihydrotestosterone in Castration-Resistant Prostate Cancer. Journal of Investigative Medicine 60:2, pages 504-507.
Crossref
Crossref
Nima Sharifi. (2011) Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer. Future Oncology 7:11, pages 1239-1241.
Crossref
Crossref
Olav Lindqvist. (2011) Living with Bodily Changes in Hormone-Refractory Prostate Cancer. Seminars in Oncology Nursing 27:4, pages 309-316.
Crossref
Crossref
Sheng Tai, Yin Sun, Jill M. Squires, Hong Zhang, William K. Oh, Chao-Zhao Liang & Jiaoti Huang. (2011) PC3 is a cell line characteristic of prostatic small cell carcinoma. The Prostate 71:15, pages 1668-1679.
Crossref
Crossref
Neil J. McKenna. (2011) Discovery-driven research and bioinformatics in nuclear receptor and coregulator signaling. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:8, pages 808-817.
Crossref
Crossref
G. Corona, E. Baldi & M. Maggi. (2011) Androgen regulation of prostate cancer: Where are we now?. Journal of Endocrinological Investigation 34:3, pages 232-243.
Crossref
Crossref
Nima SharifiMichael J. McPhaulRichard J. Auchus. (2023) “Getting from Here to There”-Mechanisms and Limitations to the Activation of the Androgen Receptor in Castration-Resistant Prostate Cancer. Journal of Investigative Medicine 58:8, pages 938-944.
Crossref
Crossref
Nima Sharifi. (2010) Standard androgen deprivation therapy for prostate cancer. Drug Discovery Today: Therapeutic Strategies 7:1-2, pages 5-8.
Crossref
Crossref